Race Oncology (ASX:RAC) Activates First Australian Clinical Site for RC220 Trial
Race Oncology (ASX:RAC) initiates its first Australian clinical site for the Phase 1 RC220 trial, marking a significant step in advancing cancer treatment.
Race Oncology (ASX:RAC) initiates its first Australian clinical site for the Phase 1 RC220 trial, marking a significant step in advancing cancer treatment.
Gold Mountain Limited (ASX:GMN) announces a $3.05m entitlement offer and appoints a new director to support its exploration initiatives.
Bioxyne Limited (ASX:BXN) secures a $7 million manufacturing agreement with NectarTek, significantly increasing FY2026 revenue projections.
Biome Australia Limited (ASX:BIO) secures a $5.0 million debt facility with NAB to drive growth and enhance financial stability.
Synlait Milk Limited (ASX: SM1) secures future milk supply with majority of cease notices withdrawn, ensuring adequate volumes for FY26 and FY27.
Epsilon Healthcare Limited (ASX:EPN) enters voluntary administration, resulting in leadership changes and subdued operations.
Cettire Limited (ASX:CTT) assesses the impact of new US tariffs on EU goods, affecting 41% of H1-FY25 sales.
Bigtincan Holdings Limited (ASX:BTH) announces a proposed acquisition by Big Wombat and outlines share and option schemes for shareholder approval.
Fisher & Paykel Healthcare (ASX:FPH) outlines its response to new US tariffs, detailing operational and financial strategies.
Ramelius Resources (ASX:RMS) reports record cash flow and announces acquisition of Spartan Resources, strengthening its market position.